Persistent hyperparathyroidism and its predictive factors in end-stage renal disease patients after kidney transplantation: A prospective study.
4 affiliations
- 1Department of Physiology-Pathophysiology-Immunology-Pharmacology, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- 2Department of Endocrinology, Cho Ray hospital, Ho Chi Minh, Vietnam.
- 3Department of Urology, Cho Ray hospital, Ho Chi Minh, Vietnam.
- 4Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Abstract
Hyperparathyroidism (HPT) may persist in patients after kidney transplantation (KT). A better understanding of which patients are likely to have persistent HPT after KT would help in the development of optimal management strategies. Our aim was to examine the prevalence of persistent HPT after KT in a contemporary cohort and to identify risk factors associated with persistent HPT at 6 months. We followed 104 KT subjects in a longitudinal prospective cohort at Cho Ray Hospital, Vietnam, from October 2023 to May 2025. Persistent HPT was defined as a parathyroid hormone (PTH) level of 150 pg/mL at 6 months after KT. Among the 104 patients, the prevalence of persistent HPT at 6 months was 58.65%. The average PTH levels pretransplant and at 6 months posttransplant were 375.70 (IQR = 259.00-603.25) pg/mL and 167.95 (IQR = 112.53-227.30) pg/mL, respectively. Patients with persistent HPT had significantly higher baseline PTH (median 489 vs 273, P < .001) and alkaline phosphatase levels (median 102.0 vs 89.5, P = .025), and also experienced longer durations of chronic kidney disease (median 5.0 vs 2.0, P = .007) and dialysis therapy (2.0 vs 1.0, P < .001). Higher pretransplant intact PTH was independently associated with persistent HPT across both multivariable models, whereas the association with dialysis duration was significant only when categorized as ≥1 year. Our findings suggest that high pretransplant intact PTH independently predicts persistent HPT at 6 months, whereas dialysis duration is only significant when it reaches 1 year or longer.
Related
- Exercise capacity and handgrip strength following dumbbell-assisted diaphragmatic breathing training in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: a prospective single-arm study
- Risk factors and predictive value of lung ultrasound aeration score for postoperative pulmonary complications in pediatric patients undergoing abdominal tumor resection: a prospective observational study
- PROMISE: a PROspective randomised double-blind parallel group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve outcomEs in patients with cirrhosis over 24 months—study protocol for a clinical trial
- Persistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms
- Predictive Value of Left Atrial Strain Combined with Low-Voltage Substrate for Recurrence After Radiofrequency Catheter Ablation in Persistent Atrial Fibrillation
BibTeX
@article{lam2026persistent,
title = {{Persistent hyperparathyroidism and its predictive factors in end-stage renal disease patients after kidney transplantation: A prospective study.}},
author = {Kim-Ngan Huynh Lam and Hen Huu Phan and Sam Minh Thai and Minh Duc Do},
journal = {Medicine},
year = {2026},
month = oct,
doi = {10.1097/md.0000000000051216},
url = {https://europepmc.org/article/MED/42888627},
note = {CC BY},
}
RIS
TY - JOUR
TI - Persistent hyperparathyroidism and its predictive factors in end-stage renal disease patients after kidney transplantation: A prospective study.
AU - Kim-Ngan Huynh Lam
AU - Hen Huu Phan
AU - Sam Minh Thai
AU - Minh Duc Do
PY - 2026
DA - 2026/10/01
JO - Medicine
DO - 10.1097/md.0000000000051216
UR - https://europepmc.org/article/MED/42888627
AB - Hyperparathyroidism (HPT) may persist in patients after kidney transplantation (KT). A better understanding of which patients are likely to have persistent HPT after KT would help in the development of optimal management strategies. Our aim was to examine the prevalence of persistent HPT after KT in a contemporary cohort and to identify risk factors associated with persistent HPT at 6 months. We followed 104 KT subjects in a longitudinal prospective cohort at Cho Ray Hospital, Vietnam, from October 2023 to May 2025. Persistent HPT was defined as a parathyroid hormone (PTH) level of 150 pg/mL at 6 months after KT. Among the 104 patients, the prevalence of persistent HPT at 6 months was 58.65%. The average PTH levels pretransplant and at 6 months posttransplant were 375.70 (IQR = 259.00-603.25) pg/mL and 167.95 (IQR = 112.53-227.30) pg/mL, respectively. Patients with persistent HPT had significantly higher baseline PTH (median 489 vs 273, P < .001) and alkaline phosphatase levels (median 102.0 vs 89.5, P = .025), and also experienced longer durations of chronic kidney disease (median 5.0 vs 2.0, P = .007) and dialysis therapy (2.0 vs 1.0, P < .001). Higher pretransplant intact PTH was independently associated with persistent HPT across both multivariable models, whereas the association with dialysis duration was significant only when categorized as ≥1 year. Our findings suggest that high pretransplant intact PTH independently predicts persistent HPT at 6 months, whereas dialysis duration is only significant when it reaches 1 year or longer.
SN - 0304-5412
SN - 1536-5964
ER -